T 0271/22 (Recombinant avian herpes virus/CEVA) of 18.06.2024
- European Case Law Identifier
- ECLI:EP:BA:2024:T027122.20240618
- Date of decision
- 18 June 2024
- Case number
- T 0271/22
- Online on
- 28 June 2024
- Petition for review of
- -
- Application number
- 13713195.9
- IPC class
- A61K 39/12C12N 15/869A61K 39/17
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Multivalent recombinant avian herpes viruses and vaccines for immunizing avian species
- Applicant name
- Ceva Santé Animale
- Opponent name
- Boehringer Ingelheim Animal Health USA Inc.
- Board
- 3.3.08
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 54European Patent Convention Art 56European Patent Convention Art 83European Patent Convention Art 123(2)Rules of procedure of the Boards of Appeal 2020 Art 012(2)Rules of procedure of the Boards of Appeal 2020 Art 012(3)Rules of procedure of the Boards of Appeal 2020 Art 012(4)Rules of procedure of the Boards of Appeal 2020 Art 012(5)Rules of procedure of the Boards of Appeal 2020 Art 012(6)
- Keywords
- Novelty - (yes)
Inventive step - (yes)
Sufficiency of disclosure - (yes)
Amendments - allowable (yes)
Amendment to case - requirements of Art. 12(2) RPBA 2020 met (no)
Amendment to case - reasons for submitting amendment in appeal proceedings (no)
Amendment to case - amendment within meaning of Art. 12(4) RPBA 2020
Amendment to case - admissibly raised and maintained (no)
Discretion not to admit submission - requirements of Art. 12(3) RPBA 2020 met (no) - Catchword
- -
- Cited cases
- -
- Citing cases
- -
Order
For these reasons it is decided that:
The appeal is dismissed.